<DOC>
	<DOCNO>NCT00586209</DOCNO>
	<brief_summary>To primary purpose evaluate effect L-glutamine therapy exercise endurance breath breath exercise response sickle cell anemia patient The secondary purpose assess effect L-glutamine pain ; energy appetite level ; narcotic usage ; hospital emergency room visit sickle cell pain</brief_summary>
	<brief_title>L-Glutamine Therapy Sickle Cell Anemia</brief_title>
	<detailed_description>This phase II , prospective , randomize , double-blind , placebo-controlled , parallel-group , study evaluate safety efficacy oral L-glutamine therapy patient sickle cell anemia sickle IS°-thalassemia least 18 year old focus aspect exercise endurance . In study , patient orally take L-glutamine placebo twice daily , clinical hematological parameter monitor . The adverse event , especially attributable L-glutamine therapy , also monitor . The data obtain essential understanding role L-glutamine therapy sickle cell anemia sickle B°-thalassemia .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>To eligible participate study , patient must meet follow inclusion criterion : Patient least 18 year age . Patient diagnose sickle cell anemia sickle ß0thalassemia ( document hemoglobin electrophoresis ) . Patient least two episode painful crisis within 12 month screen visit . If patient treat antisickling agent within three month screen visit , therapy must continuous least three month intent continue next 14 month . Patient patient 's legally authorize representative give write informed consent . If patient female childbearing potential , agree practice recognize form birth control course study . Patient able perform exercise tolerance test If patient meet follow criterion , patient must enrol : Patient significant medical condition require hospitalization ( sickle painful crisis ) within two month screen visit . Patient diabetes mellitus untreated fast blood sugar &gt; 115 mg/dL . Patient prothrombin time International Normalized Ratio ( INR ) &gt; 2.0 . Patient serum albumin &lt; 3.0 g/dl . Patient receive blood product within three week screen visit . Patient history uncontrolled liver disease renal insufficiency . Patient pregnant lactating . Patient treat experimental antisickling medication/treatment ( except hydroxyurea ) within 30 day screen visit . Patient treat experimental drug within 30 day screen visit . There factor would , judgment investigator , make difficult patient comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>L-glutamine</keyword>
	<keyword>Sickle Cell Anemia ( homozygous heterozygous )</keyword>
	<keyword>Sickle ß0-Thalassemia</keyword>
</DOC>